Masimo Corporation, a California-based manufacturer of noninvasive patient monitoring technologies, has reported total revenue of $98.76m, for the first quarter ended April 3, 2010, an increase of 15.5 %, compared to $85.49m for the comparable period in 2009.

Masimo has posted a net income attributable to Masimo Corporation of $26.7m for the first quarter of 2010, or $.044 per diluted share, compared $13.02m, or $00.22 per diluted share, for the prior year period. Operating income was $40.78m, compared to $20.08m for the year ago period.

During the first quarter, Masimo has shipped 37,100 Masimo SET pulse oximetry and Masimo Rainbow SET Pulse CO-Oximetry units, excluding handheld units, compared to 27,700 in the same period last year. Masimo estimates its worldwide installed base as of April 3, 2010 to be approximately 757,000 units, up 16% from approximately 651,000 for the same period last year.

Joe Kiani, chairman and CEO of Masimo, said: “Masimo’s mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and new applications. Toward this mission, we made solid progress through double-digit growth in our core Masimo SET pulse oximetry and a 71% increase in sales of Masimo Rainbow Pulse CO-Oximetry, which includes the first-ever continuous and noninvasive hemoglobin measurement.

“The 34% year-over-year growth in unit shipments of Masimo SET and Masimo Rainbow monitors and OEM boards reflects strong sales to OEMs and growing demand for both our Rainbow platform, and Patient SafetyNet system for the general floor.”